Azalea Acquires Healthcare Data Analytics Company dashboardMD

VisiQuate, a provider of AI-powered advanced analytics solutions to healthcare providers and medical device makers, announced a new $50 million equity investment from Sixth Street Growth.

According to VisiQuate, its AI-driven virtual data assistant Ana lets users get tailored insights by asking simple questions. Ana also suggests follow-up actions that produce even more comprehensive results. The company’s data management and analytics solutions let healthcare organizations explore complex data from multiple sources to gain insights and create actionable workflows quickly.

“We consider tackling the nearly trillion dollars of administrative waste in healthcare as a moral imperative. To fuel that vision, we are partnering and collaborating with Sixth Street, which is well-aligned with our vision,” said Brian Robertson, VisiQuate Founder & CEO.

Brian Robertson added: “Our mission is to help health care providers dramatically improve clinical, financial, and operational outcomes. Sixth Street’s deep capital, wide-ranging expertise, and stellar reputation in the healthcare industry make them ideal partners to help us fulfill our mission and vision.”

“We look forward to supporting Brian and the VisiQuate team as they continue to build analytics solutions for healthcare providers that are both more advanced and easier to use,” said Bo Stanley, Partner, and Co-Head of Sixth Street Growth.

Bo Stanley added: “Informed by their crowdsourced AI and ML capabilities, VisiQuate’s enterprise-class offerings and advanced data integration technologies make it possible for providers to dramatically reduce cost, increase yield, and improve time to revenue. We are excited to partner with them as they enter their next phase of growth and continue to lead the advanced analytics and intelligent process automation field.”

Healthcare Data Analytics companies secured $906 million in venture capital funding in Q1 2021. Mendel, an AI-powered software platform that analyses clinical data, including medical history and genetic information, raised $18 million in Series A funding.